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Abstract
Background: The potential human health risks from graphene inhalation exposure have attracted substantial
scientific interest as a result of the numerous exciting potential commercial applications of graphene. However,
the long-term distribution of graphene in organisms after inhalation is unknown, largely as a result of challenges
associated with accurate graphene quantification.
Methods: Carbon-14 labeled FLG was used to quantify the in vivo distribution of FLG in mice after oral gavage or
intratracheal instillation for up to 3 or 28 days after exposure, respectively.
Results: Intratracheally instilled FLG was mainly retained in the lung with 47 % remaining after 4 weeks. Exposure
to non-labeled FLG resulted in dose-dependent acute lung injury and pulmonary edema, but these effects were
alleviated with time despite the continued presence of FLG in the lungs. One percent and 0.18 % of the intratracheally
instilled FLG was present in the liver and spleen, respectively, after 14 days by passing through the air-blood barrier, a
finding supported by the results of oral gavage experiments which did not show detectable absorption through the
gastrointestinal tract. In addition, 46.2 % of the intratracheally instilled FLG was excreted through the feces 28 d after
exposure.
Conclusions: Quantitative measurements revealed the elimination mechanism for FLG and its biodistribution for two
exposure pathways. Graphene persistence in the lung only caused transient pulmonary effects. The in vivo distribution,
elimination, and toxicity results provided here measured using a robust quantitative method support the human health
risk assessment of graphene.
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Background
Graphene is a flat monolayer of carbon atoms tightly
packed into a two-dimensional lattice and has a number
of potential applications due to its unique intrinsic prop-
erties [1–5]. When considering the potential human
health risks of nanoparticles, inhalation is thought to be
the exposure route of highest concern [6–9]. The calcu-
lated deposition fraction of few layer graphene (FLG)
with different lateral dimensions ranging from 0.001 to
100 μm in the nasopharyngeal, tracheobronchial, and al-
veolar regions revealed that there would be substantial
deposition of these nanoplatelets throughout the respira-
tory tract [6].
Findings from several recent studies indicate that gra-
phene and graphene oxide (GO) may induce the acute
inflammation and pulmonary fibrosis in mice lungs [6–9].
However, these studies have not quantified the persistence
of graphene/GO in the mice lungs after a long exposure
time (Additional file 1: Table S1). Nanoparticles may
translocate to extrapulmonary organs and may be redis-
tributed to other tissues after deposition in the lung
[10–12]. Thus, knowledge of graphene biodistribution in
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mice after inhalation remains a key research gap. One sig-
nificant challenge for measuring graphene biodistribution
is that methods are not available for reliable graphene
quantification graphene in tissues. While a single study re-
ported the short-term biodistribution and pulmonary tox-
icity of GO in mice by using 125I-labeled GO [13],
quantitative results were only provided for the first 12 h
and the biodistribution results from this study are ques-
tionable because a fraction of the labeled 125I ions was
found to be released from the GO conjugate [14]. In
addition, the structure of graphene substantially differs
from that of GO, which contained five- and six-
membered-ring lactols and more than 40 % oxygen, and
thus the pulmonary toxicity and biodistribution of gra-
phene may similarly differ [15, 16].
In this study, 14C-labeled FLG were utilized to quantify
the in vivo distribution and excretion of graphene in
mice up to 28 days and 3 days after intratracheal instilla-
tion or oral gavage, respectively. The 14C-labeled gra-
phene was utilized because the carbon-14 atoms were
stably bound to the graphene skeleton. Potential toxico-
logical effects from non-labeled FLG exposure were also
assessed. Both the acute and long-term toxicity after
intratrachael instillation and the impact of graphene on
the microbial community composition of intestinal flora
after oral gavage were evaluated.
Results and discussions
Graphene properties
The atomic ratio of C:O in the FLG was determined using
X-ray photoelectron spectroscopy to be 89:6 (the
remaining 5 % is 1.4 % of H and 3.6 % of N) [17]. Notably,
the oxygen was introduced by the adding 14C-phenol in
FLG synthesis, not by oxidation. In addition, the oxygen
percentage is ~6 %, which is significantly lower than that
for GO [15, 16]. The specific radioactivity of the purified
FLG was 16.12 ± 0.59 mCi g-1 (n = 3). From the
characterization results of atomic force microscopic
(AFM) (see Fig. 1), the thickness of suspended FLG was
measured to be 0.97 to 3.94 nm and 72 % of total count
was in range of 1.2 to 2.1 nm. Given that the graphene
interlayer distance is 0.35 ± 0.01 nm [18, 19], the FLG
mainly consisted of 4 to 6 layers (>72 %). In addition,
AFM measurements showed that the FLG graphene had a
continuous lateral size distribution from 60 to 590 nm and
two main peaks at 90 nm and 365 nm. The hydrodynamic
diameter of graphene suspended in 0.1 % Tween 80 saline
has three peaks with average sizes at 100, 390 and
1250 nm (Fig. 1d). The smaller two peaks are in accord-
ance with results measured by AFM, while the larger peak
may be due to formation of graphene aggregates. Light
microscopy images showed large black dots which were
regarded to be graphene aggregates (Fig. 1e), which would
agree with the dynamic light scattering (DLS) results.
Distribution of graphene in mice
Distribution results after inhalation exposure for 1 day
reveal that the radioactivity in the lung, large intestine,
small intestine, stomach and feces was 85, 3, 2, 1.5 and
4.6 % of the exposed dose at 1 day (Fig. 2a), respectively;
uncertainty values for biodistribution results are pre-
sented in the figures. The radioactivity in lung, large in-
testine, small intestine and stomach gradually decreased
over time, while the radioactivity in the feces increased
over time and was detectable in liver and spleen after
7 days post exposure. However, 47 % of the exposed
dose remained in the lung after 4 weeks. Radioactive
FLG concentrations in the brain, heart, kidney, testis,
muscle and blood were always below the detection limit.
To confirm translocation of the FLG, the large intestine,
small intestine and stomach after exposure for 1 d (mea-
sured to be 1.3, 2.1, and 2.8 %, respectively, of the initial
intratracheally instilled dose) were collected, washed and
then characterized using Raman spectroscopy (Fig. 2c).
We observed D and G bands which are distinctive of
graphitic materials (the D band represents the disorder
present in sp2-hybridized carbon systems, while the G
band represents the stretching of C-C bonds), thereby
confirming the presence of the FLG in each tissue [20].
Experiments were conducted to assess the relationship
between FLG spiked to tissues and the intensity of the
Raman signals. As shown in Additional file 1: Figure S1,
neither the peak area nor height were linearly correlated
with the concentrations of FLG tested (2 to 8 % of the
initial intratracheally instilled dose of 14C-FLG). Thus,
Raman spectroscopy using the method described in this
manuscript was suitable to confirm the presence of FLG
but was not quantitative. The potential for the formation
of degradation products in tissues (liver, stomach, small
intestine, large intestine and lung) was assessed for or-
ganisms 14 d after exposure using GC-MS, HPLC, and
LSC, as described in the Method section. Additional
chemical peaks were not found in the extraction solution
using either HPLC or GC-MS. The radioactivity readings
in the extraction solution after liquid scintillation count-
ing were not statistically different from the background
value. As such, detectable FLG degradation was not ob-
served in any tissue. Additional experiments were per-
formed to determine the recovery of potential FLG
degradation products from organism tissues. Because it
was unclear which degradation byproducts could be
formed by metabolic processes in the organisms, FLG
degradation products were produced by the Fenton reac-
tion [21] and used to test the recovery. Results showed
that unmodified FLG in the tissue was not extractable
using this procedure, but that the recovery of the degrad-
ation products (spiked to liver tissues at a radioactivity
concentration that was 1 % of the initial intratracheally in-
stilled dose of 14C-FLG) ranged from 73 to 93 % (see
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Additional file 1: Figure S2). It is possible that the FLG
was modified in the tissues (i.e., oxygen-containing func-
tional groups were introduced to the surface of FLG), but
additional specific characterization measurements are
needed to determine such changes to FLG as FLG are not
extractable from the tissues. The decreasing concentration
of FLG in the liver during the 28 d exposure period may
be attributable to FLG being translocated to other tissues
or degradation products in the liver that were quickly ex-
creted and therefore not detectable through our analyses.
The considerable FLG concentration measured in di-
gestive organs (stomach, small intestine and large intes-
tine), suggests that FLG was cleared from lung and
delivered to other extrapulmonary organs. To explore
this process further, bronchoalveolar lavage fluid (BALF)
lavaged from graphene treated mice was collected and
centrifuged. Cellular precipitate was washed using saline
and resuspended for analysis using LSC. As shown in
Fig. 3a, radioactivity was detected in the alveolar macro-
phages of the FLG treated mice, while the radioactivity
of the cells in the control experiments that BALF was
extracted from control mice (not exposed to FLG) was
below the detection limit indicating the absence of de-
tectable artifacts from the separation process. Fig. 3b
and c provide visual evidence of FLG particles contained
in the alveolar macrophages of exposure group but not
the control group. The macrophages were sectioned and
its electron micrograph was shown in Fig. 3d. Fig. 3d
Fig. 1 Characterization of FLG using AFM and DLS. a Histogram of flake thickness for FLG (n = 214); b Histogram of lateral flake size for FLG
(n = 214); c Representative AFM image of FLG deposited onto mica; d Size distribution of FLG dispersed in 0.1 % Tween 80 saline measured by DLS;
e FLG suspension (0.5 mg/mL, suspend in 0.1 % Tween 80 saline) observed under light microscopy
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shows a low magnification transmission electron micros-
copy (TEM) image of macrophages containing black par-
ticles. These particles were confirmed to be FLG using
selected area electron diffraction patterns (SADP), which
showed well-defined diffraction spots confirming the
crystalline structure of the particles (Fig. 3e, f and g),
and high resolution TEM which revealed visible ordered
graphite lattices and the interlayer distance is about
0.344 nm (Fig. 3h and i), which is the interlayer distance
of graphite [22]. FLG was found in the cytoplasm of al-
veolar macrophages, which indicates FLG was phagocy-
tized by the alveolar macrophages after intratracheal
instillation. Thus, FLG could be cleared from lung
through two possible routes: i) removal by mucociliary
clearance and swallowed into the digestive system; ii) or
elimination of the phagocytized FLG by alveolar macro-
phages through the tracheobronchial tree towards the
larynx, a path previously shown to play an important
role in eliminating nanoparticles from the lung [23, 24].
As shown in Fig. 2a, ~1 and 0.18 % of the exposed
dose was also observed in liver and spleen at 14 days,
suggesting that FLG administered to the lung has en-
tered into blood circulation. FLG may pass through the
air-blood barrier into blood and then be delivered to
liver and spleen, or enter into the blood via adsorption
through the gastrointestinal tract. To assess the possibil-
ity of gastrointestinal adsorption and to test FLG
biodistribution after oral gavage, we gave mice a single
dose of graphene via gavage and quantified the radio-
activity in blood and major tissues during a 3 d exposure
Fig. 2 Biodistribution and clearance of 14C-graphene in male ICR mice after a intratracheally instillation or b oral gavage (5 μg 14C-graphene
exposed) at different time points. c Raman spectra of the FLG obtained from stomach, small intestine, large intestine and lung after exposure for
1 d. Mouse feces were collected by metabolism cages. Data for the brain, heart, kidney, testis, muscle and blood for parts A and B and also the
liver and spleen for part B were not shown because the radioactivity was always below the detection limit. The recovery of graphene in each
organism tissue was in the range of 89 to 93 %. The data in the figure was corrected by these recovery values. The symbol‘*’indicates values that
differed significantly from the control group at P ≤ 0.05. Data are presented as mean ± standard deviation (n = 5)
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period (Fig. 2b). While the stomach, small intestine,
large intestine, and feces contained 3, 4, 6 and 85 % of
the exposed dose at 12 h, respectively, most of the FLG
(>98 %) were excreted to the feces after 48 h exposure.
No radioactivity was detected in blood, heart, liver,
spleen, kidney, brain, lung, urine or testes after a single
gavage, thus indicating that FLG are unable to be
absorbed into blood circulation via the gastrointestinal
tract at detectable concentrations. Similarly, Yang et al.
reported that GO was not able to be adsorbed by the di-
gestion system after oral feeding and became undetect-
able in all organs after 1 week; however, this studied
using an external radioactive label which is a less reliable
analytical approach [25]. Similarly, multiwall carbon
nanotubes administrated by oral gavage were completely
excreted after 12 h via feces, and there was no accumu-
lation of nanoparticles in liver and spleen [26]. If a small
fraction of the intratracheally instilled FLG was acciden-
tally swallowed into the GI tract during administration
of the suspension, this would only impact the 1 d results
given the near complete excretion of orally administered
FLG within 48 h. Thus, FLG found in the liver and
spleen after intratracheal installation passed through the
air-blood barrier and was then directly translocation into
blood circulation [27–29]. Conhaim and coworkers re-
ported that the lung epithelial barrier was best fitted by
a three-pore–sized model, including a small number
(2 %) of large-sized pores (400 nm pore radius), an inter-
mediate number (30 %) of medium-sized pores (40 nm
pore radius), and a very large number (68 %) of small-
sized pores (1.3 nm pore radius) [30]. Considering the
wide distribution range of graphene sizes in our study
(see Fig. 1), a fraction of graphene likely passed the air-
blood barrier and was translocated to liver and spleen.
Fig. 3 a FLG content in macrophages collected from the mice of the control experiment and FLG treated group (5 μg, 28 days), background
radioactivity was subtracted; light microscope of macrophage collected from BALF of mice (b, control group; c, FLG-treated); d) TEM image of a
whole BALF cell from FLG-treated mice; e), f) and g) SADPs taken from p1, p2 and p3 positions, respectively; h) High resolution TEM image taken
from the p2 position; i) Fourier transfer spectra of Figure H. The symbol‘*’indicates values that differed significantly from the control group at P≤ 0.05.
Data are presented as mean ± standard deviation (n = 3)
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Li et al applied 125I labeled GO to study its distribution
in Kunming mice by intratracheal instillation and found
that the radioactivity was detected in blood and organs,
including liver, spleen and thyroid gland [13]. However,
this study only assessed the biodistribution after 12 h.
Pulmonary toxicity of graphene
We performed assays of neutrophil infiltration, cell in-
jury, and lung edema to evaluate the potential acute pul-
monary effects from different FLG doses (5 and 50 μg)
(see Fig. 4) after 24 h post exposure. The total cell
counts were five times higher in the tested group (50 μg)
compared to the control group, which indicates that in-
flammatory cell infiltration likely occurred [31]. The ob-
served difference of the BALF total protein and lactate
dehydrogenase (LDH) level between the control group
and the tested group of 50 μg was a factor of 4 and 27
fold higher, respectively, suggesting that the FLG had
caused a degree of cell injury [32]. Because some studies
show that nanoparticles may interfere with toxicity as-
says leading to artefacts [33, 34], additional experiments
were conducted which confirmed that our results were
not impacted by artefacts as discussed in the Additional
file 1: Figure S3.
The lung wet/dry mass ratio is a simple but useful in-
dicator to assess severity of lung edema, which often
arises from the leakage of fluid from capillaries into the
interstitial and alveolar spaces and the loss of lung’s abil-
ity to pump fluid out of the space [35]. We found that
exposure of 50 μg FLG caused a moderate pulmonary
edema to mice as evidenced by the change in the dry to
wet mass ratio (Fig. 4d). Lungs collected from mice of
control and the tested dose groups (5 and 50 μg) were
also analyzed by morphological and pathological obser-
vation (Fig. 5). The lungs treated with 5 μg FLG exhibit
no abnormal appearance via morphological observation.
However, most of the lung lobes (treated with 50 μg)
turned black due to distribution of FLG throughout the
lung (Fig. 5). Pathological observation of hematoxylin-
eosin (H&E) stained lung sections suggested that the
alveoli’s structure in control group was integrated and
only few cells were found. However, lungs from FLG
treated mouse exhibited mild to moderate interstitial
edema and parenchymal edema, which was also evi-
denced by the change of lung wet/dry ratio (in Fig. 4d).
This finding is supported by the presence of multiple
lung macrophages in the alveolis of the high dose expos-
ure group (Fig. 5). Similar results were reported in a
study that examined the appearance and pathological
section of lungs collected from mice which were treated
with 50 μg dispersed graphene and found graphene uni-
formly distributed in the lung and only minimal lung in-
flammation [8]. However, Schinwald et al found graphene
induced ganulomatous lesion formation and the exposure
dose in their study was also 50 μg [6].
To explore the time-dependent toxicity of graphene
after intratracheal instillation, H&E and Masson staining
were applied to examine pathological changes of lung
tissue. As shown when control Fig. 6 (a) is compared to
Fig. 6 (b), moderate interstitial and parenchymal edema
was observed in H&E stained lung sections after expos-
ure for 1 day. Severe inflammatory cell infiltration were
Fig. 4 FLG causes acute pulmonary toxicity characterized mainly by cell injury and lung edema 24 h post exposure. a BALF total cell count;
b BALF total protein; c LDH activity; d The lung wet/dry weight ratio used to evaluate the severity of lung edema. The symbol‘*’and‘**’indicates
values that differed significantly from the control group at P≤ 0.05 and P≤ 0.01, respectively. Data are presented as mean ± standard deviation (n = 6)
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also observed, which was characterized by substantial
quantities of cells in the pulmonary alveoli. Though the
severity was reduced, minimal pulmonary edema and in-
flammatory infiltration was also observed after 7 days
(Fig. 6 (c) compared to control Fig. 6 (a)). However, no ob-
vious abnormal pathological changes and lung structure
damage were found in lung sections 28 days later despite
the continued presence of approximately 47 % of the ini-
tial FLG dose in the lungs which are observed as small
black areas in Fig. 6 (d). Similar results were previously re-
ported for graphene platelets which only caused minimal
inflammation in mouse lungs after 6 weeks exposure [9].
We further examined Masson stained lung sections for
the evidence of fibrosis at 1, 7 and 28 d. However, there
was little evidence of lung fibrosis in mice treated with
FLG, regardless of different exposure time (Fig. 6). Ag-
gregates of carbon nanotubes and aggregated graphene
have been shown to induce peribronchiolar lung fibrosis
21 d or longer after their administration [8, 36]. It is
possible that improving the dispersion state of graphene
such as the usage of Tween 80 to disperse FLG in this
study may reduce the likelihood of lung fibrosis forma-
tion. Importantly, it was found that graphene dispersed
with a pluronic surfactant did not show fibrogenic
Fig. 5 The morphological observation and representative H&E stained images of the lungs harvested 24 h post exposure (a and a’ control group;
b and b’, 5 μg exposed dose; c and c’, 50 μg exposed dose). Sections were analyzed blindly and representative images selected from 6 mice per
treatment group are shown. Blue arrows: cells in alveoli; red arrows: parenchymal; black arrows: interstitial edema
Fig. 6 H&E (a, b, c, d) and Masson (a’, b’, c’, d’) stained lung sections of mice which were exposed 50 μg FLG at different time points post
exposure (a and a’ were control group at 1 day post exposure; b and b’ were 1 day post exposure; c and c’ were 7 days post exposure; d and d’
were 28 days post exposure). Sections were analyzed blindly and representative images selected from 6 mice per treatment group are shown.
Blue arrows: cells in alveoli; red arrows: parenchymal; black arrows: interstitial edema
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effects in cells or mice while these effects were observed
when the same nanomaterial was suspended with bovine
serum albumin [37]. Previous studies have shown that
GO oxide can cause damage to macrophages, and that
the lateral size of the graphene can impact the toxicity
to cells and mice with larger GO particles having higher
toxicity [37–40]. Additional work is needed to compare
FLG to GO of an individual sheet but with similar lateral
size and surface chemistry (e.g., oxygen content) to assess
the impact of GO thickness on the toxicity response.
Influence of graphene on intestinal flora
FLG was excreted via the intestinal tract regardless of
exposure via oral gavage or intratracheally instillation
(see Fig. 2). During passage of FLG through the gut
tract, graphene may impact the intestinal microbial com-
munity structure. Bacteroidetes, Firmicutes and Proteo-
bacteria are the three main microbial communities in
gut of mice and account for more than ninety percent of
the total gut flora. While the quantity of Proteobacteria
was similar between the control and graphene-treated
mice (Fig. 7), the relative abundance of the other two
predominant bacterial communities in mice statistically
differed. The relative abundance of Firmicutes in mice
exposed to FLG was decreased by 10 ± 1.2 % compared
to the control group while the relative abundance of
Bacteroidetes was increased (see Fig. 7). Previous studies
revealed that obesity is associated with changes in the
relative abundance of the two dominant bacterial divi-
sions, Bacteroidetes and Firmicutes [41]. However, we
did not find that the FLG exposure affected the body
weight of mice by monitoring the body weight change of
mice during exposed period (Additional file 1: Figure
S4), potentially as a result of an exposure period too
short to observe the weight change or a lack of sensitiv-
ity for mice to this degree of change in the microbiome.
A previous study demonstrated that carbon nanotubes
have broad-spectrum antibacterial effects against gut
bacteria [42], but this is the first in vivo report of FLG’s
biological effects on gut bacteria. It is important to note
that previous studies have shown toxicological effects of
graphene oxide on bacteria [43, 44]. While this study fo-
cused on the intestinal microbial community structure
through analysis of the DNA in the feces, it would be
important to also investigate potential toxicological ef-
fects on the remaining bacteria in the gut tract. In con-
trast to studies testing the direct toxic effects of
graphene family materials on bacteria in in vitro systems,
graphene during passage through the gut tract of organ-
isms after intratracheal installation may be covered by
surfactants or biomolecules from the lung or digestive
system and thus have a different toxicity. Further re-
search is also needed to clarify the extent to which long-
time graphene exposure in the digestive system would
alter the intestinal microbial community structure, cause
body weight changes, and potentially have a harmful ef-
fect on the test organisms.
Conclusions
Intratracheally instilled graphene was mainly retained in
the lung with 47 % remaining after 4 weeks. Exposure to
non-labeled graphene resulted in dose-dependent acute
lung injury and pulmonary edema, but these effects were
alleviated with time despite the continued presence of gra-
phene in the lungs. Intratracheally instilled graphene was
redistributed to the liver and spleen by passing through
the air-blood barrier, a finding supported by the results of
oral gavage experiments which did not show detectable
Fig. 7 Relative abundance of mice intestinal microbial community structure at phylum level. The symbol‘*’indicates values that differed significantly
from the control group at P≤ 0.05. Data are presented as mean ± one standard deviation (n = 3)
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absorption through the gastrointestinal tract. The in vivo
distribution, elimination, and toxicity results provided
here measured using a robust quantitative method sup-
port the human health risk assessment of graphene.
Methods
Materials and animals
Synthesis, purification, and characterization of 14C-la-
beled FLG were described in our previous studies [17,
21, 45]. Briefly, graphene sheets were successfully syn-
thesized by graphitization and exfoliation of sandwich-
like FePO4/dodecylamine hybrid nanosheets and then
purified using hydrochloric acid to remove the iron cata-
lysts to below the limit of detection using ICP-OES
(>5 μg/L). Liquid scintillation counting (LSC) and mass
spectrometry analyses could not detect the formation of
carbon-14 byproducts from the synthesis, purification,
or dispersion processes [17].
14C-labeled FLG powder was dispersed in 0.1 % Tween
80 saline and ultrasonicated in an ice-water bath for 3 h
to 3.5 h (100 W, JY88-II, Nanjing Immanuel Instrument
Equipment Co.). Probe sonication was performed using
a 3 s “on”/ 2 s “off” pulse sequence with a probe tip that
placed approximately 0.4 cm from the bottom of the
container [21]. Our preliminary results of XPS con-
firmed that sonication using this procedure for up to
10 h did not change the elemental composition of the
FLG (see Additional file 1: Figure S5). Prior to adminis-
tration, graphene solutions were re-dispersed using
ultrasonication for 30 min. Light microscopy, DLS and
AFM was applied to characterize the dispersion state
and particle size distribution of suspended FLG in the
dispersion medium. For optical microscopy, a droplet of
graphene suspension (0.5 mg/mL) was placed on a glass
slide and covered with a coverslip. Images were captured
at 40× magnification using NIS-Elements software
(Nikon, Japan). The particle size distribution of dispersed
FLG was characterized by using DLS (ZetaPALS, Broo-
khaven Instruments Corp., USA) at the scattering angle
θ = 90°. The standard spherical particle models were
used to convert the DLS autocorrelation functions to z-
average sizes. Five runs and one minute run duration
were set for each measurement. AFM images of FLG
were recorded using a MultiMode V8 scanning probe
microscope (Bruker, German). Samples for AFM were
prepared by dropping the highly dispersed aqueous sus-
pension of FLG on a freshly cleaved mica surface. After
the samples were dried, the AFM images were measured
using a ScanAsyst Mode. The commercially available
AFM cantilever tips with a force constant of ∼ 0.4 new-
ton/m and resonance vibration frequency of ∼ 70 kHz
(Bruker, USA) were used.
Four-week-old male ICR mice were purchased from the
laboratory animal research center of Jiangsu University.
The animals were housed in plastic cages, and provided
with water and feed ad libitum. Before being employed in
experiment, all animals were acclimated to the laboratory
environment for 1 week. Ambient conditions were at
25(±3) °C, 50(±5)% relative humidity, and a 12/12 h light/
dark cycle. The mice were treated humanely according to
Regulations on Laboratory Animals (China), and the pro-
tocols were approved by the Animal Care and Use Com-
mittee of NGH.
Distribution of graphene in mice via intratracheal
instillation
Twenty-five mice were randomly divided into five
groups of five mice each. Mice were anesthetized with
10 % chloral hydrate (280 to 350 mg/kg body weight).
Fifty μL of 14C labeled FLG suspension (0.1 mg/mL,
1.3 × 105 dpm) was delivered directly into the lung of
each mouse via intratracheal instillation. The dose of
FLG in the lung was 5 μg. After exposure, each mouse
was housed individually in a metabolism cage to collect
feces separately. One group of mice was sacrificed at 1,
7, 14, 21 and 28 days post exposure by dislocation of the
vertebrae. The lungs of mice were then lavaged three
times with 800 μL of 4 °C sterile saline to collect BALF
[46]. Then, their tissues, including brain, heart, lung,
liver, spleen, kidney, testis, small intestine, large intes-
tine, muscle and blood were harvested. All tissues, blood
and feces were freeze-dried (Labconco, America) and
ground into powder. 25 mg to 35 mg of ground tissue,
blood, or feces was combusted using a biological oxidizer
(BO, OX-500, Zinsser Analytic, Germany) at 900 °C for
4 min under a stream of oxygen gas running at 360 mL/
min. The 14CO2 released during the combustion process
was captured in alkaline carbon-14 scintillation cocktail
(Zinsser Analytic, Germany) and then analyzed by LSC.
The recovery of graphene in each organism tissue was in
the range of 89 to 93 %; the reported data for each tissue
was corrected by these recovery values. The minimum de-
tection limit of LSC and BO was measured to be 3.85 ng
14C graphene and 0.14 ng 14C graphene per milligram tis-
sue, respectively, values which determined from the signal
from blank samples plus three times the standard devi-
ation of the blank samples.
The FLG in the stomach, small intestine, large intestine
and lung at 1d was respectively collected, washed in se-
quence using DI water, dichloromethane, n-hexane and
dichloromethane, and then characterized using Raman
spectroscopy (XploRA PLUS system, Horiba Scientific,
532 nm incident radiation). Different doses of 14C-FLG
were spiked with 4 mg liver (dry mass) to test the Raman
response of FLG (see Additional file 1).
To assess potential metabolic products from the FLG,
each tissue (liver, stomach, small intestine, large intestine
and lung) at 14 d after exposure was freeze-dried, ground
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into powder, and extracted in sequence using dichloro-
methane (5 mL), n-hexane (5 mL), and dichloromethane
(5 mL). These solutions were recombined, and subjected
to anhydrous sodium sulfate to remove the water. Then,
the sample was dried using a gentle nitrogen stream and
reconstituted in methanol and dichloromethane (4:1, v/v)
for HPLC and GC-MS analysis, (see Additional file 1).
The radioactivity in the extraction was also analyzed using
LSC. To test the recovery of this extraction proced-
ure, a known amount (1 % of the initial intratrache-
ally instilled dose) of 14C-degradations products
produced by the Fenton reaction [21] or un-modified
FLG were spiked to the powder of livers from control
mice and the extraction procedure was performed
(see Additional file 1).
Low speed centrifugation (850 g, 10 min) was per-
formed to obtain cellular fraction of BALF. The obtained
cellular precipitate was washed >5 times using saline
until the radioactivity in the eluate was not detectable
(<100 dpm) by LSC. Then, the cellular precipitate was
resuspended in saline and sonicated by ultrasonic pro-
cessor to break up cells. The FLG was quantified by
measuring the radioactivity in the cell suspension using
LSC. To assess possible adsorption of FLG on cell mem-
branes during the process to separate the FLG from the
BALF cells or incomplete FLG removal, control experi-
ments were conducted. BALF extracted from control
mice (not exposed to FLG) were mixed with 50 μL 14C
labeled FLG suspension. Within five minutes after mix-
ing, low speed centrifugation was performed to obtain
cellular fraction, the BALF cellular precipitate was
treated by following the procedures mentioned above
and the FLG was quantified. A drop of cell suspension
was placed on a glass slide and covered with a cover
glass. Then, a glass slide was put under an optical mi-
croscopy and bright field images of BALF cells were
taken. Meanwhile, parts of the obtained BALF cells were
washed with physiological saline, prefixed in 3 % glutar-
aldehyde at 4 °C overnight, and then post-fixed in 1 %
osmium tetroxide. After dehydration and resin embed-
ding, BALF cells were sectioned to 50 to 60 nm thick,
and stained with uranyl acetate and lead citrate [47].
The structure of graphene particles in cells was identi-
fied using high resolution TEM imaging together with
corresponding SADP on a 200 kV FEI Tecnai TF20
FEG-TEM [48].
Distribution of graphene in mice via oral gavage
Twenty mice were randomly selected and 100 μL 14C la-
beled graphene suspension (0.1 mg/mL, 2.6 × 105 dpm)
was delivered into the stomach of each mouse via oral
gavage. The dose of FLG was 10 μg in total. After one
single exposure, each mouse was housed individually in
a metabolism cage to collect feces and urine separately.
At each sampling time (12, 24, 48, 72 h), 5 mice were
sacrificed and their blood and major tissues, including
brain, heart, lung, liver, spleen, kidney, testis, small intes-
tine, large intestine and stomach were harvested. All
organ samples and blood were freeze-dried (Labconco,
America) and ground into powder. Twenty-five mg to
35 mg powder of tissues and feces and 0.1 mL urine was
combusted using BO and the released 14CO2 analyzed
by LSC. The recovery of graphene in urine and blood
was 97(±1.2)% (n = 3); uncertainties always indicate one
standard deviation.
Pulmonary toxicity of graphene
Acute toxicity experiments of FLG to lung were per-
formed to assess potential effects at two graphene dos-
ages. Eighteen mice were randomly assigned to control
and two FLG-treated groups. After being anesthetized,
mice were intratracheally instilled with 50 μL of a con-
trol solution without graphene or a non-labeled FLG
suspension (0.1, or 1 mg/mL) that were prepared as
described above for the carbon-14 labeled FLG. Twenty-
four h later, all mice were killed by dislocation of verte-
brae. BALF was collected as described above and then
centrifuged for 10 min (210 g, 4 °C) to obtain the cellu-
lar fraction and supernatant. The cellular fraction was
resuspended in 1 % BSA/saline. Twenty μL of the cell
suspensions were pipetted onto a hemocytometer cham-
ber, and the cells were counted manually. The super-
natant was kept at −80 °C for total protein and LDH
assays using commercial kits (Nanjing Jiancheng Bioeng.
Inst., China). To calculate the lung wet/dry mass ratio,
the left lung was cut and rinsed using saline. Water on
the surface of lung was drained with filter paper. The
lung was weighed, then dried in a vacuum freeze drier
(Labconco, America) for 72 h and reweighed to deter-
mine wet/dry mass ratio. Histological examination was
also performed to evaluate toxicity of graphene to the
lung. The right lung was removed and fixed in 10 % neu-
tral buffered formalin overnight. The tissue was embed-
ded in paraffin, sectioned and stained with H&E to show
gross pathology. Images at 40× magnification were taken
using NIS-Elements software (Nikon, Japan) to show
higher magnification areas of the lung sections.
Eighteen additional mice were intratracheally instilled
with 50 μL of a 0.1 mg/mL FLG suspensions for longer-
term toxicity testing. Lungs of mice were harvested and
preserved in formalin for histological examination after
1, 7 and 28 days post exposure. Six mice were sacrificed
at each sampling time. Another 6 mice were exposed to
50 μL 0.1 % Tween 80 saline as control. H&E together
with Masson staining method was used to examine pos-
sible pathological changes and lung fibrosis of graphene
exposed mice [49].
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Impact of graphene on intestinal flora
Eighteen mice were divided into two groups. Nine mice
of one group were gavaged daily with 0.4 mL of 0.1 %
Tween 80 saline as control group, while the other group
were gavaged with 0.4 mL of 2.5 μg/mL FLG suspen-
sions (suspended in 0.1 % Tween 80 saline as described
above). After gavage for 28 days, mice were fasting for
12 h before dissection. Nine mice of each group were
randomly divided to be three sets and each set of parallel
has three mice. The germ free feces of each set were col-
lected from their rectums, combined, and stored in−20 °
C. One hundred mg feces samples from each set were
measured and three 100 mg samples were obtained.
Total genomic DNA was extracted from each of the
three samples using FastDNA Soil Kit (MP Biomedicals,
USA) following the manufacturer protocol. The concen-
tration and quality of the extracted DNA were deter-
mined using spectrophotometry (NanoDrop, USA) to
ensure that the DNA concentration in the samples was
greater than 200 ng/μg for the following experiments.
The samples with >200 ng/μg DNA were selected and
amplified by Polymerase Chain Reaction. The amplified
DNA samples were purified using DNA fragment purifi-
cation kit ver 4.0 (Takara, Japan) according to the rec-
ommended protocol. About 10 μg (quantified by Qbit)
of purified DNA sample was sent to Jiangsu Zhongyi-
jinda Analytical & Testing CO., LTD. (Yixing, China) for
high-throughput sequencing using Illumina’s Miseq plat-
form. Generated 16S rRNA gene sequences were proc-
essed using Mothur software.
Statistical analysis
All statistical analyses were performed using SPSS 18.0
(PASW Statistics, IBM Company); differences were con-
sidered statistically significant at p < 0.05. Errors always
represent one standard deviation and the numbers of
samples are reported with the standard deviation.
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